CMS Makes COVID-Wrought Changes to Oncology Care Model
As the COVID-19 pandemic continues to spur huge changes throughout the health care system, CMS’s current and future alternative payment models have not been immune. In early June, the Center for Medicare & Medicaid Innovation (CMMI) unveiled changes to the programs, including to the Oncology Care Model (OCM).
The changes that CMMI has implemented so far are the following:
✦The model has been extended for one year through June 2022.
✦OCM practices can forgo upside and downside risk for the performance periods impacted by the public health emergency.
✦OCM practices that remain on one- or two-sided risk can remove COVID-19 episodes from reconciliation for performance periods impacted by the public health emergency.
✦Both aggregate-level reporting of quality measures and beneficiary-level reporting of clinical and staging data are optional.
✦Cost and resource utilization reporting and practice transformation plan reporting in July/August are no longer required.
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Senior Editor, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile